Tags

Type your tag names separated by a space and hit enter

An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review.
Arch Gynecol Obstet. 2019 07; 300(1):1-6.AG

Abstract

INTRODUCTION

Bacterial vaginosis (BV) is the most common vaginal disorder in reproductive-age women. The condition is characterised by the replacement of a healthy, lactobacilli-dominated vaginal microbiota by anaerobic and facultative anaerobic bacteria. BV increases the risk of acquisition of STIs and is associated with pregnancy complications. Although the composition of the bacteria in BV varies between individuals, there are some species such as Gardnerella, Atopobium, Mycoplasma, Snethia, Megasphera, Dialister, etc., that are found most frequently.

MATERIAL AND METHODS

Literature research to the importance of Atopobium vaginae in BV and treatment options.

RESULTS

Atopobium (A.) vaginae is an important component of the complex abnormal vaginal flora in BV; even though A. vaginae, like Gardnerella vaginalis, has also been detected in the normal flora, it is much more common in BV patients. A. vaginae has been shown to play an important role in the pathophysiology of BV and is thought to be at least a partial cause of the known negative sequelae. The presence of A. vaginae in the BV-associated biofilms and its resistance to some antimicrobial substances has been described - this seems to have a major impact on treatment outcome.

CONCLUSION

Current scientific data demonstrate that dequalinium chloride (Fluomycin®) is one of the valid therapeutic options for BV treatment, since it displays a broad antimicrobial spectrum against relevant vaginal pathogens, especially against G. vaginalis and A. vaginae, without having safety concerns.

Authors+Show Affiliations

German Center for Infections in Obstetrics and Gynaecology, Wuppertal, Germany. w.mendling@t-online.de.Labfit-HPRD: Health Products Research and Development, Lda, Covilhã, Portugal. CICS-UBI: Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal.Scientific and Medical Department, Medinova AG, Zurich, Switzerland.Scientific and Medical Department, Medinova AG, Zurich, Switzerland.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

30953190

Citation

Mendling, Werner, et al. "An Update On the Role of Atopobium Vaginae in Bacterial Vaginosis: what to Consider when Choosing a Treatment? a Mini Review." Archives of Gynecology and Obstetrics, vol. 300, no. 1, 2019, pp. 1-6.
Mendling W, Palmeira-de-Oliveira A, Biber S, et al. An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review. Arch Gynecol Obstet. 2019;300(1):1-6.
Mendling, W., Palmeira-de-Oliveira, A., Biber, S., & Prasauskas, V. (2019). An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review. Archives of Gynecology and Obstetrics, 300(1), 1-6. https://doi.org/10.1007/s00404-019-05142-8
Mendling W, et al. An Update On the Role of Atopobium Vaginae in Bacterial Vaginosis: what to Consider when Choosing a Treatment? a Mini Review. Arch Gynecol Obstet. 2019;300(1):1-6. PubMed PMID: 30953190.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review. AU - Mendling,Werner, AU - Palmeira-de-Oliveira,Ana, AU - Biber,Stephan, AU - Prasauskas,Valdas, Y1 - 2019/04/05/ PY - 2019/01/23/received PY - 2019/03/26/accepted PY - 2019/4/7/pubmed PY - 2020/4/9/medline PY - 2019/4/7/entrez KW - Atopobium vaginae KW - Bacterial biofilm KW - Bacterial vaginosis KW - Clindamycin KW - Dequalinium chloride KW - Metronidazole KW - Microbial resistance SP - 1 EP - 6 JF - Archives of gynecology and obstetrics JO - Arch Gynecol Obstet VL - 300 IS - 1 N2 - INTRODUCTION: Bacterial vaginosis (BV) is the most common vaginal disorder in reproductive-age women. The condition is characterised by the replacement of a healthy, lactobacilli-dominated vaginal microbiota by anaerobic and facultative anaerobic bacteria. BV increases the risk of acquisition of STIs and is associated with pregnancy complications. Although the composition of the bacteria in BV varies between individuals, there are some species such as Gardnerella, Atopobium, Mycoplasma, Snethia, Megasphera, Dialister, etc., that are found most frequently. MATERIAL AND METHODS: Literature research to the importance of Atopobium vaginae in BV and treatment options. RESULTS: Atopobium (A.) vaginae is an important component of the complex abnormal vaginal flora in BV; even though A. vaginae, like Gardnerella vaginalis, has also been detected in the normal flora, it is much more common in BV patients. A. vaginae has been shown to play an important role in the pathophysiology of BV and is thought to be at least a partial cause of the known negative sequelae. The presence of A. vaginae in the BV-associated biofilms and its resistance to some antimicrobial substances has been described - this seems to have a major impact on treatment outcome. CONCLUSION: Current scientific data demonstrate that dequalinium chloride (Fluomycin®) is one of the valid therapeutic options for BV treatment, since it displays a broad antimicrobial spectrum against relevant vaginal pathogens, especially against G. vaginalis and A. vaginae, without having safety concerns. SN - 1432-0711 UR - https://www.unboundmedicine.com/medline/citation/30953190/An_update_on_the_role_of_Atopobium_vaginae_in_bacterial_vaginosis:_what_to_consider_when_choosing_a_treatment_A_mini_review_ L2 - https://dx.doi.org/10.1007/s00404-019-05142-8 DB - PRIME DP - Unbound Medicine ER -